Literature DB >> 34253913

Camrelizumab efficacious in NPC.

David Killock1.   

Abstract

Year:  2021        PMID： 34253913     DOI： 10.1038/s41571-021-00542-9

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.

Authors:  Yunpeng Yang; Song Qu; Jingao Li; Chaosu Hu; Mingjun Xu; Weidong Li; Ting Zhou; Liangfang Shen; Hui Wu; Jinyi Lang; Guangyuan Hu; Zhanxiong Luo; Zhichao Fu; Shenhong Qu; Weineng Feng; Xiaozhong Chen; Shaojun Lin; Weimin Zhang; Xiaojiang Li; Yan Sun; Zhixiong Lin; Qin Lin; Feng Lei; Jianting Long; Jinsheng Hong; Xiaoming Huang; Lingzhi Zeng; Peiguo Wang; Xiaohui He; Ben Zhang; Qing Yang; Xiaojing Zhang; Jianjun Zou; Wenfeng Fang; Li Zhang
Journal:  Lancet Oncol       Date:  2021-06-23       Impact factor: 41.316
  1 in total
  1 in total

1.  JUPITER-02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps.

Authors:  Laura Ling Ying Tan; Quynh-Thu Le; Nancy Ying Ying Lee; Melvin Lee Kiang Chua
Journal:  Cancer Commun (Lond)       Date:  2021-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.